WNT3A and melanoma: Treating WNT3A-expressing melanoma spheroids with PLX4720 led to a decrease in spheroid size and in the number of invasive cells with respect to PLX4720-treated, GFP-derived spheroids or DMSO-treated, WNT3A-derived spheroids [194].